初发2型糖尿病胰岛素治疗剂量的门诊观察

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (6): 687-690.

初发2型糖尿病胰岛素治疗剂量的门诊观察

唐平, 杨川¹, 李莉², 曾映娟¹, 杜婧¹

深圳市罗湖区人民医院内分泌科, 深圳 518001, 广东;
¹中山大学附属第二医院内分泌科, ²急诊科, 广州 510120, 广东

收稿日期:2006-01-20 修回日期:2006-03-03 出版日期:2006-06-26 发布日期:2020-12-04
作者简介:唐平,女,本科,主治医师,主要从事内分泌内科临床工作。Tel:0755-21295380 E-mail:lhyytp@yahoo.com.cn

Dosage of insulin treatment on newly diagnosed type 2 diabetics

TANG Ping, YANG Chuan¹, LI Li², ZENG Ying-juan¹, DU Jing¹

Department of Endocrinology, LuohuDistrict, People's Hospital, Shenzhen 518001, Guangdong, China;
¹Department of Endocrinology, ²Emergency Department, the Second Affiliated Hospital of Zhongshan University, Guangzhou 510120, Guangdong, China

Received:2006-01-20 Revised:2006-03-03 Online:2006-06-26 Published:2020-12-04

摘要/Abstract

摘要： 目的: 探讨门诊首次诊断糖尿病人应用胰岛素进行治疗的剂量。方法: 32 名门急诊糖尿病人,分别应用双相门冬氨酸胰岛素30(商品名:诺和锐30) (20 例) 及诺和灵30R(12 例) 进行血糖控制, 观察血糖的变化, 调整胰岛素的用量。结果: 初次诊断时空腹血糖(FPG)、餐后2 h 血糖(PPG) 两组间无统计学差异。两种胰岛素治疗1 周后两组间空腹血糖(FPG) 无统计学差异, 而诺和锐30 组餐后2 h 血糖(PPG) 低于诺和灵30R 组(P<0.05);达到血糖控制标准时, 诺和锐30 组达标时间较诺和灵30R 组短(P<0.05);血糖控制达标后继续观察1 个月, 诺和锐30 组胰岛素维持剂量低于诺和灵30R 组(P<0.05)。结论: 对于门诊初次发现糖尿病的患者, 应用诺和锐30 的效果可能较诺和灵30R 更加显著。

关键词: 2 型糖尿病, 胰岛素类似物, 血糖

Abstract: AIM: To study the insulin dosage on newly diagnosed type 2 diabetics.Methods: Thirty-twonewly diagnosed type 2 diabetics were treated by biphasic insulin aspart 30(BIAsp30) (group Asp30, n=20) and Novolin 30R (group Novolin 30, n=12) respectively. The levels of plasma glucose and insulin dosage were evaluated.Results: There were no significant change in fasting plasma glucose and postprandial glucose before treatment in the two groups.After one week's treatment there was no significant change in fasting plasma glucose in both groups, while the postprandial plasma glucose in Asp30 was significantly lower than that in Novolin 30(P<0.05).When the controlling of plasma glucose meets the standard, the time costed in group Asp30 was significant lower compared with group Novolin 30.The maintenance dosages before breakfast and before dinner were also significantly lower in group Asp30 than that in group Novolin 30 (P<0.05) in further observation.Conclusion: It is better to use BIAsp30 than to use Novolin 30R on newly diagnosed type 2 diabetics.

Key words: type 2 diabetes, insulin analogue, plasma glucose

中图分类号:

唐平, 杨川, 李莉, 曾映娟, 杜婧. 初发2型糖尿病胰岛素治疗剂量的门诊观察[J]. 中国临床药理学与治疗学, 2006, 11(6): 687-690.

TANG Ping, YANG Chuan, LI Li, ZENG Ying-juan, DU Jing. Dosage of insulin treatment on newly diagnosed type 2 diabetics[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(6): 687-690.

参考文献

1 Iikova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E.Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment[J].Diabetes Care, 1997, 20:1353-6
2 祝方, 纪立农, 韩学尧, 朱宇, 张红杰, 周翔海, 等.短期胰岛素强化治疗诱导初诊2 型糖尿病患者血糖长期良好控制的临床实验[J].糖尿病杂志, 2003;11:5-9
3 Lebovitz H.Postprandial hypergly caemec state:importance and consequences[J].Diabetes Res Clin Pract, 1998;40:S27-8
4 Balkau B, Shipley M, Jarrett R.High blood glucose concentration is a risk factor for mortality in middle-aged non-diabetic men.20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policeman Study[J].Diabetes Care, 1998;21:360-7
5 Tominaga M, Eguchi H, Manaka H, Igarishi K, Kato T, Sekikawa A.Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose[J].Diabetes Care, 1999;22:920-4
6 Hermansen K, Colombo M, Storgaard H, Ostergaard A, Kolendorf K, Madsbad S.Improved postprandial glycemic contros with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes[J].Diabetes Care, 2002;25:883-8
7 Mcsorley P, Bell P, Jacobsen L, Kristensen A, Lindholm A. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30:a double-blind cross-over study in people with Type 2 diabetes[J].Clin Ther, 2002;24:530-9
8 Overmann H, Heinemann L.Injection-meal interval:recommendations of diabetologists and how patients handle it[J].Diabetes Res Clin Pract, 1999;43:137-42
9 Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L.Use of inslulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes[J].Diabetes Care, 2000;23:583-8
10 Boehm B, Home P, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily:a randomized trial in Type 1 and Type 2 diabetic patients[J].Diabet Med, 2002;19:393-9
11 Weyer C, Heise T, Heinemann L.Insulin aspart in a 30/70 premixed formulation.Pharmacodynamic properties of a rapidacting insulin analog in stable mixture[J].Diabetes Care, 1997; 20:1612-4

[1]	陈以宁, 肖云, 韩晓雨, 黄璐璐, 马景胜, 熊寒斌, 傅毓, 汪保林, 郭晓晖, 钟林, 敖检根, 何佳珂. 肝移植术后排斥合并高血糖的诊治和用药的实践与思考[J]. 中国临床药理学与治疗学, 2023, 28(5): 550-555.
[2]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[3]	黄凯歌, 许勤华, 王伟. 血糖、血钙对急性重症胰腺炎患者预后影响的交互作用及预测效能研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1227-1234.
[4]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[5]	李玲玲, 张洋洋, 白佳, 杨虹, 杨莹, 吕海宏. 不同胰高血糖素样肽-1受体激动剂对骨代谢影响的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(11): 1315-1320.
[6]	王春江，孙伟，孙林丽. 甲巯咪唑致中国人群胰岛素自身免疫综合征的临床特点分析[J]. 中国临床药理学与治疗学, 2020, 25(2): 209-213.
[7]	原丽，韩玲娜，常永丽，张翠英. 肠促胰岛素类似物拮抗APP/PS1转基因鼠认知功能损伤的研究[J]. 中国临床药理学与治疗学, 2019, 24(7): 721-729.
[8]	姚佳，乔迪，郭鑫，崔昌萌. 桑叶中1-脱氧野尻霉素对糖尿病肾病大鼠的治疗作用[J]. 中国临床药理学与治疗学, 2018, 23(5): 517-523.
[9]	雷强. 胃癌根治术后应激性高血糖与肠道黏膜屏障功能的相关性考察[J]. 中国临床药理学与治疗学, 2017, 22(4): 471-476.
[10]	寿岚，娄国强. 2型糖尿病合并慢性乙肝对血糖控制的影响分析[J]. 中国临床药理学与治疗学, 2016, 21(9): 1046-1049.
[11]	周晓隆，陈志武. 黄蜀葵花总黄酮对实验性高血糖大鼠的作用及机制初探[J]. 中国临床药理学与治疗学, 2016, 21(6): 617-620.
[12]	代曼云，罗敏，林韩特，刘爱明. 贝特类抗高血脂药物药理活性研究新进展[J]. 中国临床药理学与治疗学, 2016, 21(11): 1306-1312.
[13]	黄昭穗，杨骄，黄昭瑄，栾丽丽，王赐玉，杨红英. 利拉鲁肽在血糖控制不佳的T2MD伴肥胖患者中临床疗效观察[J]. 中国临床药理学与治疗学, 2016, 21(1): 87-92.
[14]	刘长乐, 龚成欣, 熊超鹏, 何鹿玲, 饶燊强, 肖雯, 彭露露, 汤澜, 许永虎, 徐宏. 体重指数影响骨钙素基因HindIII多态性与中国绝经前妇女空腹血糖间的关联[J]. 中国临床药理学与治疗学, 2015, 20(9): 1026-1031.
[15]	伍艳, 吴翠芳, 汪江林. 利西拉来治疗2型糖尿病的有效性及安全性的Meta分析[J]. 中国临床药理学与治疗学, 2015, 20(2): 167-174.